Anivance AI combines Taiwan’s internationally renowned semiconductor and manufacturing expertise with AI and life sciences, ushering in a new era of smart drug discovery. By integrating AI-powered organ-on-a-chip technology with high-throughput automated workflows, and building a global ecosystem, Anivance AI delivers human-relevant data that accelerates preclinical testing and improves decision-making for a better protection of human health and animal welfare.
Institutional membership
The Scientific Committee Pro Anima works to open up dialogue (between all stakeholders, with civil society), promote scientific advances, and support researchers, biotech and start-ups developing and/or using technologies and new methods, alternatives to animals, for research, education and toxicology.
You are an industry, a start-up, a lab or an institution
Support Pro Anima with a CORPORATE / INSTITUTION MEMBERSHIP
Join our growing network of companies, start-up and biotech committed to advancing innovative, humane, and scientifically reliable methods applied to biomedical research and toxicology testing.
Among the benefits of Corporate / Institution membership:
- Visibility: Gain visibility within our network in bringing your support to the pionneering work of Pro Anima in France and in Europe;
- Updates & Communication: Stay informed and share your research and services with the weekly NAMs newsletter, the newsletter dedicated to the latest developments in New Approach Methodologies in Europe and worldwide;
- Exclusive Access to the NAMs Interface and other resources
Corporate and Institutional members receive privileged access to our NAMs Interface – a unique database gathering resources on NAMs, laboratories, companies, events, and more.
Corporate / Institution membership
For more information and/or support a specific action of our Committee, contact us.
Our first members
Anivance AI
Ansys
Ansys, Inc. is an American software company specializing in computer-aided engineering. The group notably develops medical simulation tools with high clinical value, such as the in silico pyAnsysHeart project produced by the Ansys healthcare research team to model the human heart using Ansys LS-DYNA software.
Today, Ansys is part of Synopsys, Inc., leader in silicon-to-systems engineering solutions.
Kreatis
Founded in 2014 by ecotoxicologist Dr. Paul Thomas, KREATiS is an in silico R&D company. It develops high-precision QSAR models predicting human and environmental toxicity and physicochemical properties of organic molecules, replacing animal testing (3Rs principle).
Combining experimental data and advanced algorithms, it provides reliable predictions according to regulatory requirements, thus reducing costs and delays.
